Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile by Byrn, Stephen R. et al.
Research Article
Analysis of Two Commercially Available Bortezomib Products: Differences
i nA s s a yo fA c t i v eA g e n ta n dI m p u r i t yP r o f i l e
Stephen R. Byrn,
1,5 Patrick A. Tishmack,
2 Mark J. Milton,
3 and Helgi van de Velde
4
Received 23 February 2010; accepted 30 November 2010; published online 1 April 2011
Abstract. The analytical properties of two commercially available bortezomib products (VELCADE
®
and Bortenat) were compared using nuclear magnetic resonance, mass spectrometry, high-performance
liquid chromatography, and gas chromatography. The data showed differences between the two products.
Based on these data, Bortenat samples contained more active ingredients than indicated by the label
(mean, 116.5% and 117.9% of label, in 2-mg and 3.5-mg vials, respectively). In comparison, VELCADE
samples contained a mean of 99.3% of active ingredient, which was consistent with the approved
speciﬁcation range (US, 90–110%; EU, 95–105%). Clinical data demonstrate that patients exposed to
higher than recommended doses of bortezomib on the standard twice-weekly dosing schedule are likely
to have an increased risk of major toxicities. Bortenat 2-mg vials contained an isovaleraldehyde impurity;
the origin of this is unknown. Additionally, the ratio of boronic acid to boronic ester differed between
Bortenat 2 mg (0.27:1) and 3.5 mg (0.13:1) and VELCADE (0.10:1) samples reconstituted in saline
indicating that the Bortenat product is not equivalent to the VELCADE product.
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INTRODUCTION
There is an increasing interest in comparing the physical
and chemical properties of drug products sold throughout the
world. A recent paper has outlined the different physical and
chemical properties of various recombinant human erythro-
poietin products sold around the world. This study showed
signiﬁcant differences between such large protein products,
with drug products from Korea, India, and China containing
more glycoforms and other impurities compared with the
innovator product manufactured by Amgen, Inc. (1). The
results of this study prompted an investigation comparing two
drug products containing the small molecule proteasome
inhibitor bortezomib, a product made in India (Bortenat, Natco
Pharma) and the innovator product (VELCADE
®, Millennium
Pharmaceuticals, Inc., and Janssen-Cilag), which is
manufactured in the United States and Europe. VELCADE
has had its new drug application (NDA) approved by the
United States Food and Drug Administration (US FDA) and
holds the marketing authorization application approved by the
European Medicines Agency.
Bortezomib is a modiﬁed dipeptidyl boronic acid. The
chemical name for bortezomib, the monomeric boronic acid,
is [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcar-
bonyl) amino] propyl]amino]butyl] boronic acid (2). VEL-
CADE is approved in the US for the treatment of patients
with multiple myeloma and for the treatment of patients with
mantle cell lymphoma following at least one prior therapy (3).
In the European Union (EU) (4) and Canada, VELCADE in
combination with melphalan and prednisone is an approved
treatment for patients with previously untreated multiple
myeloma who are ineligible for high-dose therapy and stem
cell transplantation. In these countries and in many other
countries worldwide, VELCADE is also approved as a single-
agent treatment for patients with multiple myeloma who have
received at least one prior therapy. The chemical structure of
bortezomib (the free boronic acid) is shown in Fig. 1a (2).
The drug product is provided as a mannitol boronic ester,
Fig. 1b, which, in reconstituted form, consists of the mannitol
ester in equilibrium with its hydrolysis product, the mono-
meric boronic acid (2). This equilibrium means that drug
products containing bortezomib are unique and chemically
complex. VELCADE is supplied as a lyophilized powder in
single-dose vials containing 3.5 mg bortezomib and 35 mg
mannitol, USP, which is reconstituted in 0.9% saline to a ﬁnal
concentration of 1 mg/1 mL and administered by intravenous
injection (2). The drug substance in the solid state exists in its
cyclic anhydride form as a trimeric boroxine (2).
This paper reports the analysis of Bortenat and VEL-
CADE, and compares the analytical data for these products.
The study reported herein shows differences between borte-
zomib products produced by different manufacturers.
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Samples
Bortenat vials containing 2 mg and 3.5 mg of bortezomib
were obtained in India. The manufacturing lot numbers were
201556 and 200446, respectively. The samples were sealed with
gray elastomeric stoppers in glass vials containing the lyophi-
lized product, a white loose powder. Each 2- and 3.5-mg vial
contained 18.06 and 30.52 mg of lyophilized material, respec-
tively. VELCADE samples, in the containers in which VEL-
CADE is marketed, containing 3.5 mg bortezomib were
randomly selected from the Janssen Pharmaceutica site in
Beerse, Belgium; the manufacturing lot number was 100478/
2415-00-1486051. Samples were stored and handled according
to label conditions. The chain of custody was identical for
Bortenat and VELCADE samples, using SSCI’s standard
operating procedure for sample handling.
NMR Spectroscopy
The 1D
1H-nuclear magnetic resonance (NMR) analyses
were performed at 25°C using a Varian Unity INOVA
600 MHz NMR spectrometer at Purdue University, West
Lafayette, IN. Instruments were calibrated and maintained
according to standard practice. All spectra were acquired
using a 5 mm indirect detection triple resonance gradient
probe. The drug product was dissolved in approximately
0.6 mL of either DMSO-d6 or a solution of 0.9% NaCl in 10%
D2O/90% H2O. The NMR spectra were acquired using the
following parameters: 14 ppm spectral width, 7.4 μs pulse
width, 3 s acquisition time, 40 scans, 960 Hz B1 ﬁeld strength
for transmitter saturation of the water resonance for 5 s
during the pulse delay, 50,400 acquired data points zero-ﬁlled
to 131,072 data points for Fourier transformation, and 0.2 Hz
exponential multiplication to improve the signal-to-noise
ratio.
Mass Spectrometry
The direct infusion mass spectra analyses were per-
formed using a Waters Acquity TQD mass spectrometer at
PPD, Madison, WI. Samples were prepared by adding 2 mL
of water to a 2-mg vial of Bortenat to achieve a ﬁnal sample
concentration of 1 mg/mL. The instrument parameters used
are shown in Table I.
GC/MS Analysis
The headspace gas chromatography mass spectrometry
(GC/MS) analyses were performed using an Agilent 6890N
GC instrument equipped with an MSD (Agilent 5973N) and a
headspace autosampler (Agilent 7694) at PPD, Madison, WI.
Instruments were calibrated and maintained according to
standard practice and were qualiﬁed for the analysis per-
formed herein. Drug product samples were prepared by
adding 2 mL of water to 2- and 3.5-mg vials. One milliliter
of this solution was added to a 10 mL headspace vial. A DB-
Wax column (60 m×0.32 mm ID, 1 μm ﬁlm thickness) was
employed. The headspace autosampler had the following
settings: oven temperature, 75°C; loop temperature, 11°C;
and transfer line temperature, 140°C. The GC temperature
program was 40°C (4 min), 10°C/min, and 220°C (20 min).
The injector port was 220°C. Helium gas was used at a ﬂow
rate of 1 mL/min with a split ratio of 5:1.
GC/FID Analysis
The GC/ﬂame ionization detector (FID) analyses were
performed using an Agilent 6890N GC instrument equipped
with a headspace autosampler (Agilent 7694) at PPD, Madison,
WI. A DB-Wax column (60 m×0.32 mm ID, 1 μm ﬁlm
Fig. 1. Chemical structure of a bortezomib, [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)
amino]propyl]amino]butyl] boronic acid and b its symmetrical mannitol ester. The carbons are numbered for
reference to the NMR resonance assignments
Table I. Mass Spectrometry Instrument Parameters
Ionization mode ESI negative
Capillary (kV) 3.55
Cone (V) 40
Extractor (V) 3
Source temperature (°C) 90
Probe temperature (°C) 130
Desolvation gas ﬂow (L/h) 400
Cone gas ﬂow (L/h) 20
Scan range (amu) 100–600
Syringe pump (μL/min) 20
462 Byrn et al.thickness) was employed. Instruments were calibrated and
maintained according to standard practice and were qualiﬁed
for the analysis performed herein. The settings of the autosam-
pler and GC were the same as for GC/MS, except that the ﬂow
rate was increased to 3.5 mL/min. The FID temperature was
260°C with a hydrogen ﬂow rate of 35 mL/min, air at 400 mL/
min, and make up gas helium 25 mL/min. The t-butanol
standard was prepared at 0.04 mg/mL, isovaleraldehyde was at
0.025 mg/mL, and isobutyl formate, t-butylacetate, and buty-
lated hydroxytoluene were at 0.01 mg/mL. Dodecamethylpen-
tasiloxane was also used to quantitate other unknown siloxane
compounds.Thedrugproductsamplepreparationwasthesame
as in GC/MS analysis.
High-Performance Liquid Chromatography
The HPLC analyses were performed at Aptuit Inc.,
Kansas City, MO. The HPLC analysis was run with a
Symmetry C18 column (250×4.6 mm ID packed with 5 μm
particles) themostated at 25°C and operated at 1.0 mL/min.
Gradient elution was used with mobile phase A (acetonitrile/
water, 30/70, v/v) and mobile phase B (acetonitrile/water, 80/
20, v/v). Both mobile phases A and B contained 0.1% formic
acid. The following gradient program was used: 100% A for
15 min, 100% A to 100% B in 15 min, and hold for 15 min.
The injection volume was 20 μL, and the UV detector was set
at 270 nm. The drug product samples were prepared by
reconstituting ten drug product vials with normal saline to
obtain a ﬁnal concentration of 1 mg/mL based on label claim.
The reported assay is based on the mean assay of ten
individual vials. This was a validated HPLC method and used
a well-characterized and qualiﬁed reference standard with a
known purity to determine differences in assay of active
ingredient. System suitability evaluation was performed prior
to each analysis. System suitability parameters were as
follows: no signiﬁcant peaks are present in the blank
chromatogram which elute in the retention window of the
drug substance or impurities; the resolution between the drug
substance and diastereomer peaks (impurities G & H) is ≥2.0
(refer to USP <621> for determination of resolution); the
number of theoretical plates for the drug substance peak is
≥2,000 (refer to USP <621> for determination of theoretical
plates); the tailing factor for the drug substance peak is ≤2.0
(refer to USP <621> for determination of tailing factor); the
%RSD of the peak area response in ﬁve consecutive
injections of working standard is ≤2.0%; the percentage
difference in average response factors between the working
and check standard injections is ≤±2.0%. The limit of
detection was 0.001% for the assay method, and the limit of
quantitation was 0.03%.
RESULTS
Characterization of Bortezomib
The Bortenat 2- and 3.5-mg and VELCADE 3.5-mg
samples were analyzed by 1D
1H-NMR spectroscopy. The
NMR spectrum of Bortenat 2 mg in DMSO-d6 was very
s i m i l a rt ot h a to ft h eV E L C A D E3 . 5 - m gs a m p l ea n d
indicated the presence of bortezomib in the Bortenat
2 mg sample. In addition, the
1H-NMR spectra indicated
the presence of free boronic acid in the aqueous solution of
0.9% NaCl in 10% D2O/90% H2O( F i g .2). Integrating the
signal from the H4 resonances revealed a boronic acid to
boronic ester ratio of approximately 0.27:1 for Bortenat
2 mg and 0.13:1 for Bortenat 3.5 mg samples. In
comparison, a boronic acid to boronic ester ratio of
approximately 0.10:1 was found in the VELCADE 3.5-mg
samples (Fig. 2).
The largest impurity observed in the
1H-NMR spectra of
the Bortenat and VELCADE samples was a compounding
solvent, t-butanol. For the 3.5-mg samples, Bortenat had
approximately 1.8 times more t-butanol than the VELCADE
sample, which is reasonably consistent with the GC result of
approximately 1.7 times more t-butanol in Bortenat
(Table II). The integral ratios of silicon-containing
impurities (silanes and siloxanes) to the combined integrals
of the H4 resonances of the boronic acid and ester in the
Bortenat 3.5-mg sample was 0.55:1 versus 0.10:1 for the
VELCADE 3.5-mg sample (Fig. 3). A similar result was also
observed in the spectra of the DMSO-d6 solutions. For the
Bortenat 2-mg samples, this ratio was 0.12:1. The Bortenat
1H-NMR spectra had four or more separate low-frequency
peaks characteristic of silicon-containing impurities while the
VELCADE spectra had one or two peaks (Fig. 3).
The NMR spectra of both VELCADE and Bortenat in
aqueous solutions were also collected at 0 and 180 min. The
resulting boronic acid to ester ratios were the same at both time
points, indicating that the difference between VELCADE and
Bortenat persists long after equilibrium is expected to be
achieved. The bortezomib to mannitol ratio was higher for
Bortenat than VELCADE (0.55:1 versus 0.33:1), which is likely
to be one reason that the boronic acid to ester ratios are
consistently maintained in aqueous solution.
The slight peak shifting observed in Fig. 2 is attributed
to chemical exchange. The peaks that shift are not from the
exchanging protons (OH and/or NH) because the water
resonance dominates most of the exchanging protons and
prevents them from being observed under these conditions.
The peak shifting may be caused by the variable exchange
of mannitol protons in the Bortenat and VELCADE
samples, which then affects the peak positions of protons
several bonds away. The peak shifting may also be due to
differences in the acid/ester equilibrium, which is clearly
different for Bortenat and VELCADE (Fig. 2). The
observed chemical shifts are determined by the popula-
tion-weighted average chemical shift of each environment
experienced by the exchanging protons even though they do
not produce observable peaks in the spectra. The peak shifting
was not due to a systematic referencing error because the
aromatic protons of the benzyl group in the spectra of both the
Bortenat and VELCADE samples were essentially superimpos-
able under these conditions, which is consistent with the fact that
these aromatic protons would be almost entirely unaffected by
chemical exchange.
The Bortenat 2-mg sample was also analyzed by the
direct-infusion MS method. The mass spectrum of the
Bortenat 2-mg sample in aqueous solution clearly showed a
peak for boronic ester (m/z 529) and a peak for free boronic
acid (m/z 383) (data not shown). The Bortenat solution was
also monitored at 2, 5, 8, and 24 h by MS, and the relative
ratio of ester to free acid was constant.
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The amount of bortezomib present (assay) in the
Bortenat 2- and 3.5-mg vials and VELCADE 3.5-mg vials
was analyzed using a validated HPLC method. Ten vials of
each product were analyzed individually. The mean value of
ten vials was reported as the overall assay for each
bortezomib product, as shown in Table III, along with the
content uniformity of each product. The assays of Bortenat
2 mg (116.5%) and 3.5 mg (117.9%) were above the approved
speciﬁcation limit for assay of bortezomib in VELCADE;
90.0–110.0% in the US and 95–105% in the EU. In addition,
Bortenat 2-mg vials showed a higher level of total impurities
(0.96%) than Bortenat 3.5 mg (0.23%) and VELCADE
3.5 mg (0.28%) vials.
Analysis of Impurities and Volatile Compounds
Headspace GC/MS analysis identiﬁed 13 volatile com-
pounds in the Bortenat 2-mg vials, and 17 in the Bortenat 3.5-
mg vials, compared with six in the VELCADE 3.5-mg vials.
Table II lists the volatile compounds identiﬁed by GC/MS and
quantitated by GC/FID. All samples contain t-butanol, which
is used as a compounding solvent. Two unknown siloxane
derivatives were found in VELCADE 3.5-mg vials at trace
levels (0.08–0.11 μg/vial). Six and 14 unknown siloxane
derivatives were observed in Bortenat 2- and 3.5-mg vials,
respectively, at concentrations of 0.08–3.74 and 0.08–20.21 μg/
vial. Isovaleraldehyde, a compound typically found in fra-
grance and ﬂavoring agents, was also detected in the Bortenat
2-mg vials (3.83 μg/vial) but not in the Bortenat 3.5-mg vials
or in the VELCADE samples. The source of this material is
not known.
DISCUSSION
The ﬁnding that the Bortenat samples analyzed did not
comply with the US- and European-approved regulatory
assay limits and contained higher than labeled amounts of
active drug has potential clinical consequences. If this
bortezomib-containing product were administered in accord-
ance with the approved single-agent dose and schedule for
VELCADE in patients with multiple myeloma (1.3 mg/m
2 on
days 1, 4, 8, and 11 every 3 weeks), the potencies of 116.5%
and 117.9% determined for the Bortenat 2-mg and 3.5-mg
vials would result in the equivalent administration of 1.51 and
1.53 mg/m
2 bortezomib, respectively, at each dosing. There
are several indications in the medical literature (5–8) as well
as in publicly available regulatory review documents from the
US FDA (9) and European Medicines Agency (10) that
administering bortezomib at doses greater than 1.3 mg/m
2 on
the standard biweekly schedule increases the incidence of
toxicities known to be associated with bortezomib use.
This increase in toxicity with higher bortezomib dose has
been demonstrated in several clinical trials. An early dose-
ﬁnding phase I study of bortezomib using the standard
biweekly schedule initially recommended administering bor-
tezomib at 1.56 mg/m
2 (5). This was later revised to 1.3 mg/m
2
(10,11) due to dose-limiting toxicities that included diarrhea
and painful sensory neuropathy (5,9,10). Across a variety of
Fig. 2. Comparison of the
1H-NMR spectra of 3.5 mg samples of a Bortenat and b VELCADE. The
samples were dissolved in 0.9% NaCl, 10% D2O/90% H2O. The region from 2.35 to 2.85 ppm shows the
resonances and integrated areas from the H4 protons of the boronic acid and ester. The H4 proton is the
proton attached to the same carbon as the boron atom in Fig. 1. The peak at ~2.73 ppm is due to the
boronic acid, and the peak at ~2.62 ppm is the boronic ester. The peak shifting is likely due to chemical
exchange differences between the two samples as described in the “Results” section
464 Byrn et al.phase I studies, the dose–toxicity relationship was conﬁrmed,
with the proportion of patients that stopped receiving
treatment due to toxicity being higher with increased dose
(10% at doses of 0.7–1.3 mg/m
2 and 30% at doses greater
than 1.3 mg/m
2)( 10). After these ﬁndings were reported, the
development of bortezomib for the treatment of multiple
myeloma continued using the standard twice-weekly schedule
with the 1.3 mg/m
2 dose (12–14). Similarly, in two separate
phase II studies investigating bortezomib using the twice-
weekly schedule in patients with advanced renal cell
carcinoma and in recurrent ovarian cancer, the initial dose
of 1.5 mg/m
2 had to be decreased to 1.3 mg/m
2 during the
course of the study as the majority of patients treated at the
1.5 mg/m
2 dose required dose reductions or premature
treatment discontinuations due to toxicity (6,8). Recently, a
case series of three patients with newly diagnosed multiple
myeloma and renal impairment reported the development of
severe neuropathy in two of these three patients after
treatment with Bortenat, at a reduced dose in the ﬁrst cycle
and at a dose of 1.3 mg/m
2 in subsequent cycles (15).
Additional differences between the two products were
identiﬁed. Bortenat 2-mg vials contained isovaleraldehyde, a
compound used in fragrances or as a ﬂavoring agent; the
origin of this compound is unknown. Bortenat also contained
higher levels of polysiloxane compounds. The toxicologic and
clinical impact of these differences is unknown. It is also
interesting to note that the NMR and MS analyses indicated
the presence of a higher proportion of free boronic acid in the
aqueous Bortenat solution. The ratio of free acid to boronic
ester was higher in the Bortenat 2-mg (0.27:1) and 3.5-mg
(0.13:1) vials than in the VELCADE 3.5-mg vials (0.10:1).
Ratio data were included in regulatory applications for
VELCADE and the ratio of boronic acid to boronic ester is
used to characterize the innovator product. These ratio data
also indicate that the Bortenat bortezomib product is not
equivalent to the innovator product. The clinical impact of
these differences is unknown.
CONCLUSION
Overall, these analyses of Bortenat and VELCADE
indicate differences between these two products. The
difference in assay results may have a clinical impact,
potentially resulting in increased toxicities if patients are
administered the Bortenat product at a dose of 1.3 mg/m
2
according to the prescribing information on single-agent
use of VELCADE.
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Table III. Assay of Bortezomib and Analysis of Impurities by HPLC in the Bortenat 2.0- and 3.5-mg Vials, and VELCADE 3.5-mg Vials
Bortenat 2.0 mg Bortenat 3.5 mg VELCADE 3.5 mg
Mean bortezomib assay (%) 116.5 117.9 99.3
Sample 1 117.2 117.7 99.5
Sample 2 115.6 117.3 98.5
Sample 3 118.0 118.7 99.7
Sample 4 116.3 116.5 100.3
Sample 5 115.9 117.2 99.0
Sample 6 116.7 119.0 99.0
Sample 7 117.9 118.3 100.3
Sample 8 114.8 117.7 98.4
Sample 9 115.7 118.7 98.5
Sample 10 117.3 117.9 99.2
%RSD (content uniformity) 0.9 0.7 0.6
Total impurities (w/wt.%) 0.96 0.23 0.28
RSD relative standard deviation
Fig. 3. Comparison of the
1H-NMR spectra of 3.5 mg samples of a Bortenat and b VELCADE. The
samples were dissolved in 0.9% NaCl, 10% D2O/90% H2O. The region from −0.10 to 0.30 ppm shows the
resonances and integrated areas of the silicon-containing compounds in each sample. The differences in the
number of peaks and their relative quantities are readily observed
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